Technology

Verndari is developing a proprietary formulation and delivery technology that will allow the company to create unique new vaccines. These new vaccines will serve large and profitable markets.

The Verndari proprietary technology is designed to

  • Enable pain-free delivery of vaccines.
  • Enable low cost delivery of vaccines.
  • Enable room-temperature stable vaccines.
  • Enable rapid response to changes in influenza as well as other infectious agents.

Verndai’s proprietary MicroArray Patch or MAP design and automated MicroArray Patch Manufacturing System or MAP MS will allow Verndari to dramatically change the delivered cost of vaccines, thus having a significant impact on healthcare globally.

Verndari MAPs have been created to achieve two imperatives.  First, when activated they must deliver a precise amount of sterile vaccine to the dermal layer.  Second, they must be capable of being produced by the millions in a ready-to-use configuration. 

We combine three technologies to achieve this outcome.  We use photochemical etching to form MAPs and shape the individual tips.  We use microfluidic dispensing to deliver a precise amount of vaccine into each individual tip.  Finally, we use integrated robotic assembly to deliver prepackaged MAPs.  Each sealed MAP packet will contain a ready-to-use miniapplicator in sterile packaging.

Our raw material is a very thin sheet of 304 stainless steel.  We use photochemical etching to create fixed planar arrays (x y axis) of individual MAPs.  Each individual tip is precisely formed and remains connected to the SS304 sheet by a pre-formed trough.  The MAPs are formed with a sharp point and chiseled edges, and each has a pre-formed well designed to subsequently receive the appropriate vaccine.

A state-of-the-art microfluidic dispensing instrument is used to deliver a precise amount of vaccine into each pre-formed well.  This microfluidic dispensing equipment is capable of simultaneously and accurately applying the fluid into hundreds of wells outlined on the stainless-steel sheet, leaving each well filled with five to ten Nano liters of vaccine.  This small amount of vaccine dries immediately and adheres to the well of the MAPs.

Figure 1a shows a 5 x 5 -1 MicroArray with 5 nL of 1% Congo Red dispensed into the well of our microtips.   This shows the accuracy and precision of the dispensing process.  Figure 1b shows a MicroArray currently in fabrication moving to a circular “happy face” format.   This format has found favor with the managers of focus groups sponsored by PATH for use in global childhood vaccine programs.   The idea is to make vaccination fun and enjoyable by creating a “tatoo happy face” that disappears after a few hours at the site of vaccine administation.

Figure 1a and 1b.  5 x 5 -1 microarray and a happy face array.

Figure 1a and 1b.  5 x 5 -1 microarray and a happy face array.

Our integrated robotic assembly manufacturing approach applies pressure to the preformed trough, mechanically brings each loaded tip to vertical, and delivers the individual MAPs for singulation and packaging operations.  The output of the line is pre-packaged sterile Verndari MAPs.  These sealed packages are oxygen and moisture free and ready for immediate use. 

All three technologies currently exist at the scale and accuracy we need.  It will require focus to integrate these technologies, but all are proven in current large scale manufacturing operations.

Vaccine Vision

A broad family of room temperature stable vaccines self administered via a painless patch...

read more
Featured Article
Featured Team Member

Dr. D. R. Henderson
Chief Executive Officer

Dan has experience and success in founding and building biopharmaceutical companies. He holds a Ph.D. in Medical Sciences from the University of New Mexico School of Medicine and was a postdoctoral scholar at Duke University Medical Center. He founded Microgenics Corporation. At Microgenics, Dan invented the CEDIA™ immunoassay system used in clinical laboratories throughout the world. CEDIA™ immunoassays now sell over $1B annually: please see www.usdiagnostics.roche.com and then search for CEDIA™ on their website; repeat at www.thermofisher.com. For this work, the American Association for Clinical Chemistry (AACC) awarded the 2015 biennial Ullman Prize for Technology Innovation to Dr. Henderson.

Dan also founded Calydon where he genetically engineered adenovirus targeting prostate cancer. For this work he was recognized as one of the two pioneers in the field of oncolytic virotherapy (Scientific American, “Tumor Busting Viruses”, October 2003). Calydon was sold to Cell Genesys. 2015 saw the first FDA approved oncolytic virus, a herpesvirus for melanoma.

Dr. Henderson also co-founded PaxVax, a manufacturer and developer of vaccines for travelers to countries without adequate water sanitation (Typhoid, Cholera and Hepatitis A) and the U.S. Military (Anthrax) (see www.paxvax.com). PaxVax was named Best Early-Stage Vaccine Biotech company at the 16th annual World Vaccine Congress in Washington, D.C., March, 2016 and received FDA approval for a Single Dose Oral Cholera vaccine in June. Dan holds 34 issued US Patents.

read more